sheddase

These programs include phase I trials for its HIV and diabetes INDs, filings of three to four more INDs by year's end, a potential milestone payment from Pfizer, and phase I and phase II trails of its sheddase inhibitor that treats tumors.

Incyte Narrows Earnings Gap 2006

"As such, we believe that Incyte shares will trade sideways until proof-of-concept data is presented from Incyte's other R&D programs including the sheddase inhibitor and diabetes programs."

Incyte Plagued With Uncertainty 2006

Turning now to our sheddase inhibitor, Incyte 7839, which is under development for breast cancer, results from the ongoing Phase 2 trial continue to demonstrate that the combination of

Incyte CEO Discusses Q3 2010 Results - Earnings Call Transcript -- Seeking Alpha 2010

I just wanted to maybe ask a couple questions about the sheddase program.

Incyte CEO Discusses Q3 2010 Results - Earnings Call Transcript -- Seeking Alpha 2010

When we started the study, adding the sheddase inhibitor to Herceptin and then to Herceptin plus chemotherapy - and what we were finding was that people who were both HER2-positive and

Incyte CEO Discusses Q3 2010 Results - Earnings Call Transcript -- Seeking Alpha 2010

Lebel A, McMahon S, Fournier I, Fugere M, et al. (2003) TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity.

PLoS ONE Alerts: New Articles Katarina Hajdin et al. 2010

Cytori: RESTORE 2 data show high level of patient and physician satisfaction Cytori reports results supporting efficacy of cell-enriched fat grafting Incyte announces positive results for selective oral sheddase inhibitor study Is Sunesis The Next 10-Bagger?

BloggingStocks 2009

- (Business Wire) Incyte Corporation (Nasdaq: INCY) announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

The Earth Times Online Newspaper 2009

For example, fusing the integrin ectodomain to vasorin's transmembrane and cytoplasmic domains precludes both sheddase and γ-secretase cleavage.

PLoS Biology: New Articles 2008

Chief Medical Officer and Director of Drug Development, Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, stated, "The results of this proof of concept study, while limited to a small number of patients, are encouraging and suggest that the combination of the sheddase inhibitor with trastuzumab may offer a new therapeutic approach in HER2 positive breast cancer.

The Earth Times Online Newspaper 2009